No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Cambridge Cognition announced on Monday that it has entered into a commercialisation agreement with India-based brain health platform Ivory to deploy its 'CANTAB Pathway' digital cognitive assessment tool across healthcare and consumer health markets in India.
The AIM-traded neuroscience technology company said the partnership marked a strategic expansion into a high-growth international market.
It said Ivory would roll out CANTAB Pathway across both professional healthcare and consumer segments, leveraging its clinical network and consumer-facing platform.
India, with a population of 1.47 billion, represents a significant opportunity, the companies said.
Of an estimated 138 million people aged over 60, as many as 34 million could be living with mild or major cognitive impairment, according to research cited from the LASI-DAD study.
Multiple studies suggested that up to 90% of cognitive impairment cases remain underdiagnosed.
"India represents a major opportunity, with a significant unmet need for earlier identification of cognitive impairment," said Rob Baker, chief executive of Cambridge Cognition.
"As health-conscious, tech-enabled populations grow, demand for proactive brain health tools is increasing rapidly.
"We believe the Ivory team shares our passion and energy to make a difference and has made impressive progress across both consumer and professional healthcare markets.
"We are excited to partner with them to expand access to CANTAB Pathway in India."
Ivory recently published what it described as India's first Brain Health Report, highlighting gaps in diagnosis and the need for scalable early screening solutions.
With no definitive cure for neurodegenerative conditions such as dementia, the focus was increasingly shifting towards prevention and early identification.
"Our founding scientists have known and used CANTAB for many years," commented Issac John, chief executive of Ivory.
"We appreciate the strong scientific pedigree of the assessments based on thousands of clinical peer-reviewed papers.
"The Cambridge Cognition team have built CANTAB Pathway to be exactly the product we need to add to our offering to enable us to pursue our mission of shifting the focus from late-stage diagnosis to proactive brain health solutions."
Cambridge Cognition said India's middle and affluent class, estimated at between 90 million and 190 million people, was increasingly focused on longevity, healthspan and access to high-quality healthcare, while younger urban populations were said to be becoming more tech-enabled and proactive in managing their health.
Under the agreement, CANTAB Pathway would be deployed at scale in India and was currently available in English and multiple regional languages including Hindi, Tamil, Telugu, Bengali and Kannada, with further language expansion planned.
At 1310 GMT, shares in Cambridge Cognition Holdings were up 11.39% at 44p.
Reporting by Josh White for Sharecast.com.